Chronic plaque psoriasis Skin and Connective Tissue Diseases Psoriasis
Conditions
Interventions
Arm A: conventional topical treatment (as per current local practice may include the following: emollients, vitamin D creams and ointments [calcipotriol etc.], tar preparations [Alphosyl and Exorex] a
Sponsors
South Devon Healthcare NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who suffer from stable chronic plaque psoriasis that would be appropriate for treatment by topical agents 2. Informed consent 3. Adults aged 18 years or over, male or female
Exclusion criteria
Exclusion criteria: 1. Pregnant women 2. Patients with severe disease 3. Patients with unstable psoriasis and putular psoriasis 4. Patients who have already experienced healing 5. Unable to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Physical Assessment: using the Psoriasis Area and Severity Index (PASI) assessment tool, validated by photographic evidence 2. Quality of Life Assessments with Dermatology Life Quality Index (DLQI) to show to which degree the psoriasis affects the patient's normal activities 3. Psychological assessment (12-item General Health Questionnaire [GHQ12]) to show if there has been any general improvement in the quality of life, regardless of the state of psoriasis 4. Health Economics Assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The Healing Assessment (HA) 1.1 will identify any possible trends in psychological triggers 2. The Healing Assessment (HA) 2.1 will be used to assess the relevance of any unusual experiences during treatment and to note the areas of the body which the healer feels may require extra attention | — |
Countries
United Kingdom
Outcome results
None listed